Table 1. PD-L1 expression and clinical characteristics of 95 PCa patients.
| Characteristic | PD-L1 + (n = 32) | PD-L1 − (n = 63) | P value |
| Age (median) | 64 | 62 | |
| PSA (ng/mL) | 9.9 | 8.0 | <0.01 |
| Gleason score (n, %) | <0.01 | ||
| 6 | 1 (3.1%) | 18 (28.6%) | |
| 3+4 | 10 (31.2%) | 30 (47.6%) | |
| 4+3 | 13 (40.6%) | 7 (11.1%) | |
| 8 | 5 (15.6%) | 5 (7.9%) | |
| 9 | 4 (12.5%) | 2 (3.2%) | |
| Pathology(n) | 0.23 | ||
| Adenocarcinoma | 29 | 62 | |
| Ductal adenocarcinoma | 1 | 1 | |
| Mucinous adenocarcinoma | 1 | 0 | |
| Adenocarcinoma with scaly area | 1 | 0 | |
| Positive surgical margin (PMS, n, %) | <0.01 | ||
| Yes | 16 (50%) | 12 (19.0%) | |
| No | 16 (50%) | 51 (81%) | |
| Lymph node involvement (n, %) | 1.00 | ||
| Yes | 3 (9.40%) | 7 (11.10%) | |
| No | 29 (90.6%) | 56 (88.9%) | |
| CD68 positive rate (%) | 71.30 | 65.10 | 0.04 |
| CD163 positive rate (%) | 42.16 | 24.39 | <0.01 |